ArticleHepatology international2020
Plasma perfusion combined with plasma exchange in chronic hepatitis B-related acute-on-chronic liver failure patients.
Article in Hepatology international, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 19 citations in OpenAlex.
- Plasma exchange-based artificial liver support system demonstrates short-term therapeutic efficacy in treating chronic severe hepatitis B.American journal of translational research · 2026Article
- Remnant cholesterol is associated with poor prognosis in patients with hepatitis B-related acute-on-chronic liver failure: a Chinese population-based study.Lipids in health and disease · 2025Observational
- Efficacy of a novel artificial liver versatile plasma purification system in patients with acute-on-chronic liver failure.World journal of gastroenterology · 2025Article
- Predicting the gastrointestinal bleeding of HBV-related acute-on-chronic liver failure based on machine learning.Frontiers in medicine · 2025Article
- Association between systemic immune inflammation index and short term prognosis of acute on chronic liver failure.Scientific reports · 2024Article
- Three Artificial Liver Models of Treatment of Acute-on-Chronic Liver Failure.Therapeutics and clinical risk management · 2024Article
- Association of direct bilirubin to total bilirubin ratio with 90-day mortality in patients with acute-on-chronic liver failure.Frontiers in medicine · 2023Article
- [Clinical study of heparin anticoagulation scheme during plasma adsorption therapy for liver failure].Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology · 2022Article
- Plasma Exchange-Based Non-bioartificial Liver Support System Improves the Short-Term Outcomes of Patients With Hepatitis B Virus-Associated Acute-on-Chronic Liver Failure: A Multicenter Prospective Cohort Study.Frontiers in medicine · 2021Article
- Leukocytes, Systemic Inflammation and Immunopathology in Acute-on-Chronic Liver Failure.Cells · 2020Review
- Dynamic Prognostication in Transplant Candidates with Acute-on-Chronic Liver Failure.Journal of personalized medicine · 2020Article
- Therapeutic Plasma Exchange in Hepatology: Indications, Techniques, and Practical Application.Journal of clinical and experimental hepatologyReview
- Low Volume Plasma Exchange and Low Dose Steroid Improve Survival in Patients With Alcohol-Related Acute on Chronic Liver Failure and Severe Alcoholic Hepatitis - Preliminary Experience.Journal of clinical and experimental hepatologyArticle
- Recognizing Dysfunctional Innate and Adaptive Immune Responses Contributing to Liver Damage in Patients With Cirrhosis.Journal of clinical and experimental hepatologyReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 1 institution in 1 country.
Funding
Abstract
BACKGROUND AND
aimsArtificial liver support systems (ALSS) have been shown to significantly reduce mortality in patients with acute-on-chronic liver failure (ACLF). However, the characteristics of patients who would benefit most from ALSS treatment are poorly understood. This study aimed to delineate the indicators for ALSS and evaluate the effectiveness of plasma perfusion combined with plasma exchange (PP + PE) in patients with hepatitis B virus-related ACLF (HBV-ACLF).
methodsA total of 898 patients with HBV-ACLF in a single center were enrolled retrospectively. Propensity score matching (PSM) was used in case-paired analysis. Hepatic or extra-hepatic organ failures were defined by Chronic Liver Failure-Sequential Organ Failure Assessment (CLIF-SOFA) criteria. Complications included ascites, infection, hepatopulmonary syndrome, hepatorenal syndrome, hepatic encephalopathy and upper gastrointestinal bleeding. Numbers of organ failures or complications were used for risk stratification.
resultsAmong all patients, 418 patients received standard medical therapy (SMT) and 480 received PP + PE plus SMT. After one-to-one paired PSM within the two groups without risk stratification, 293 pairs were enrolled. The PP + PE group displayed significantly lower mortality risk in both 28- and 90-day observation durations. When stratified, patients with two or more organ failures or complications from the PP + PE group showed greater decrease in mortality risk. Moreover, PP + PE treatment significantly increased the resolution of organ failures and complications and ameliorated the development of new organ failures and complications.
conclusionsPP + PE treatment significantly reversed organ failures and ameliorated the development of new organ failures and complications, thus reducing mortality risk of patients with HBV-ACLF.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.